Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib and Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma
NCT06553872Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2024
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in mantle cell lymphoma (MCL), sponsored by Moffitt Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06553872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553872.